Results 261 to 270 of about 92,043 (285)

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Lancet, The, 2017
Espen A Haavardsholm, Knut E A Lundin, Jørgen Jahnsen   +2 more
exaly  

Infliximab

Reactions Weekly
  +4 more sources

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Lancet, The, 2002
Juergen Braun, Matthias Schneider
exaly  

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Lancet, The, 2019
Beyong Duk Ye, Adi Lahat, Sigal Fishman
exaly  

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Lancet, The, 1999
Josef S Smolen, Paul Emery, Marc Feldmann   +2 more
exaly  

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

Lancet, The, 2005
Kristian Reich, Christopher Em Griffiths
exaly  

Infliximab

Reactions Weekly, 2009
openaire   +2 more sources

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

Lancet, The, 2012
David Laharie, Matthieu Allez, Frank Zerbib   +2 more
exaly  

Infliximab-induced aseptic meningitis

Lancet, The, 2001
Hubert Marotte
exaly  

Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial

Lancet, The, 2014
Sonia Jain, Preeti Jaggi, Jane C Burns
exaly